NASDAQ:VYNT

Vyant Bio - VYNT Stock Forecast, Price & News

$0.82

+0.01 (+1.23%)

(As of 08/12/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.80
▼
$0.82
50-Day Range: $0.66
▼
$0.98
52-Week Range: $0.60
▼
$3.24

Volume: 18,881 shs
Average Volume: 27,888 shs
Market Capitalization: $24.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Vyant Bio MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 265.9% Upside
$3.00 Price Target
Short Interest: Healthy
0.47% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.01
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.56) to ($0.49) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

494th out of 1,135 stocks

Medical Laboratories Industry

15th out of 28 stocks

3.5

Analyst's Opinion

Consensus Rating
Vyant Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Vyant Bio has a forecasted upside of 265.9% from its current price of $0.82.
Amount of Analyst Coverage
Vyant Bio has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.47% of the float of Vyant Bio has been sold short.
Short Interest Ratio / Days to Cover
Vyant Bio has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vyant Bio has recently decreased by 18.74%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Vyant Bio does not currently pay a dividend.
Dividend Growth
Vyant Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VYNT.

2.2

News and Social Media Coverage

News Sentiment
Vyant Bio has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Vyant Bio this week, compared to 0 articles on an average week.
MarketBeat Follows
2 people have added Vyant Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vyant Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.77% of the stock of Vyant Bio is held by insiders.
Percentage Held by Institutions
Only 8.71% of the stock of Vyant Bio is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Vyant Bio are expected to grow in the coming year, from ($0.56) to ($0.49) per share.
Price to Book Value per Share Ratio
Vyant Bio has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vyant Bio

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their price objective on shares of Vyant Bio to $3.00 and set a "buy" rating for the company in a research note on Tuesday, May 17th.

Vyant Bio Price Performance

Shares of NASDAQ:VYNT traded up $0.01 during midday trading on Friday, hitting $0.82. 18,881 shares of the company traded hands, compared to its average volume of 27,888. Vyant Bio has a 12-month low of $0.60 and a 12-month high of $3.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.74 and a quick ratio of 2.67. The stock has a 50-day moving average price of $0.82 and a 200 day moving average price of $0.95.

Vyant Bio (NASDAQ:VYNT - Get Rating) last announced its quarterly earnings results on Monday, May 16th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.01. The company had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.30 million. On average, equities research analysts forecast that Vyant Bio will post -0.56 earnings per share for the current fiscal year.

Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

VYNT Stock News Headlines

August 14, 2022 | americanbankingnews.com

Vyant Bio (VYNT) Set to Announce Quarterly Earnings on Monday

August 11, 2022 | nasdaq.com

Fulcrum Therapeutics, Inc. (FULC) Reports Q2 Loss, Lags Revenue Estimates

August 11, 2022 | finance.yahoo.com

Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022

August 9, 2022 | nasdaq.com

Immatics (IMTX) Reports Q2 Loss, Lags Revenue Estimates

August 3, 2022 | finance.yahoo.com

Vyant Bio to Present at Investor Summit Group's Q3 Virtual Conference

August 1, 2022 | americanbankingnews.com

Short Interest in Vyant Bio, Inc. (NASDAQ:VYNT) Decreases By 35.7%

July 20, 2022 | benzinga.com

Vyant Bio (NASDAQ: VYNT) Engages Skyline Corporate Communications Group, LLC To Continue Advancing Its Communications With The Financial Industry

June 1, 2022 | finance.yahoo.com

Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services

May 19, 2022 | finance.yahoo.com

Vyant Bio to Present at the H.C. Wainwright Global Investment Hybrid Conference

May 16, 2022 | seekingalpha.com

Vyant Bio, Inc. (VYNT) CEO Jay Roberts on Q1 2022 Results - Earnings Call Transcript

May 16, 2022 | investing.com

Vyant Bio Reports Q1 Loss from Cont. Operations of $0.15

May 16, 2022 | nasdaq.com

Vyant Bio vs. Bitcoin: Price Relationship Crosses Threshold

May 16, 2022 | proactiveinvestors.com

Vyant Bio ends 1Q with $16.4M in cash to fund small molecule therapeutics research for neurological diseases

May 16, 2022 | finance.yahoo.com

Vyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business Highlights

May 10, 2022 | finance.yahoo.com

Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022

May 5, 2022 | finance.yahoo.com

Vyant Bio Announces Participation in BioNJ’s 12th Annual BioPartnering Conference

April 13, 2022 | proactiveinvestors.com.au

Vyant Bio enters collaboration with Organo Therapeutics to find treatments for Parkinson's Disease

March 30, 2022 | uk.investing.com

Peering Into Vyant Bio Inc. - Common Stock's Recent Short Interest

March 30, 2022 | bizjournals.com

Vyant Bio forms Parkinson's drug partnership, seeks buyer for its CRO business

March 30, 2022 | proactiveinvestors.com

Vyant Bio ends 2021 with $20.6M in cash as it sharpens focus on novel drug discovery

March 30, 2022 | msn.com

Vyant Bio Shares Jump On Parkinson's Disease Agreement

March 30, 2022 | proactiveinvestors.com.au

Vyant Bio enters collaboration with OrganoTherapeutics to find treatments for Parkinson's Disease

March 30, 2022 | finance.yahoo.com

Vyant Bio Reports Fourth Quarter and Year-End 2021 Results and Provides Strategic and Business Highlights

March 29, 2022 | seekingalpha.com

Vyant Bio spikes on deal to develop drugs for Parkinson’s Disease

March 29, 2022 | finance.yahoo.com

Vyant Bio and OrganoTherapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinson’s Disease

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive VYNT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vyant Bio and its competitors with MarketBeat's FREE daily newsletter.

VYNT Company Calendar

Last Earnings: 5/16/2022
Today: 8/14/2022
Next Earnings (Confirmed): 8/15/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:VYNT
CUSIP: N/A
CIK: 1349929
Web: stemonix.com
Phone: (201) 479-1357
Fax: 201-528-9201
Employees: 40
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $3.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +265.9%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,860,000.00
Net Margins: N/A
Pretax Margin: -1,251.84%
Return on Equity: -36.84%
Return on Assets: -31.76%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 2.74
Quick Ratio: 2.67

Sales & Book Value

Annual Sales: $1.15 million
Price / Sales: 20.97
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.08 per share
Price / Book: 0.76

Miscellaneous

Outstanding Shares: 29,410,000
Free Float: 26,539,000
Market Cap: $24.12 million
Optionable: Not Optionable
Beta: 1.87

Key Executives

Mr. John A. Roberts M.B.A. (Age 63)
MBA, Pres, CEO & Director
Comp: $597.69k
Mr. Yung-Ping Yeh M.B.A. (Age 46)
M.S., P.M.P., Co-Founder & Director
Comp: $351.45k
Mr. Andrew D.C. LaFrence CPA (Age 59)
CPA, Chief Financial Officer
Comp: $355.34k
Dr. Robert Thomas Fremeau Jr. (Age 67)
Ph.D., Chief Scientific Officer
Dr. Robert J. Petcavich Ph.D. (Age 68)
Chief Science Advisor & Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VYNT Stock - Frequently Asked Questions

Should I buy or sell Vyant Bio stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vyant Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VYNT shares.
View VYNT analyst ratings or view top-rated stocks.
What is Vyant Bio's stock price forecast for 2022?: 1 equities research analysts have issued 1-year price targets for Vyant Bio's shares. Their VYNT share price forecasts range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 265.9% from the stock's current price.
View analysts price targets for VYNT or view top-rated stocks among Wall Street analysts.
How have VYNT shares performed in 2022?: Vyant Bio's stock was trading at $1.35 on January 1st, 2022. Since then, VYNT stock has decreased by 39.3% and is now trading at $0.82.
View the best growth stocks for 2022 here.
When is Vyant Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our VYNT earnings forecast.

How can I listen to Vyant Bio's earnings call?: Vyant Bio will be holding an earnings conference call on Monday, August 15th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
How were Vyant Bio's earnings last quarter?: Vyant Bio, Inc. (NASDAQ:VYNT) posted its quarterly earnings data on Monday, May, 16th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. The company had revenue of $0.30 million for the quarter, compared to analysts' expectations of $0.30 million.
What is Vyant Bio's stock symbol?: Vyant Bio trades on the NASDAQ under the ticker symbol "VYNT."
How do I buy shares of Vyant Bio?: Shares of VYNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vyant Bio's stock price today?: One share of VYNT stock can currently be purchased for approximately $0.82.
How much money does Vyant Bio make?: Vyant Bio (NASDAQ:VYNT) has a market capitalization of $24.12 million and generates $1.15 million in revenue each year.
How can I contact Vyant Bio?: Vyant Bio's mailing address is 2370 State Route 70 Suite 310, Cherry Hill NJ, 08002. The official website for the company is stemonix.com. The company can be reached via phone at (201) 479-1357, via email at jzimmons@zimmonsic.com, or via fax at 201-528-9201.

This page (NASDAQ:VYNT) was last updated on 8/14/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Vyant Bio - VYNT Stock Forecast, Price & News

Vyant Bio MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Vyant Bio

Analysts Set New Price Targets

Vyant Bio Price Performance

VYNT Stock News Headlines

VYNT Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VYNT Stock - Frequently Asked Questions

Should I buy or sell Vyant Bio stock right now?

What is Vyant Bio's stock price forecast for 2022?

How have VYNT shares performed in 2022?

When is Vyant Bio's next earnings date?

How can I listen to Vyant Bio's earnings call?

How were Vyant Bio's earnings last quarter?

What is Vyant Bio's stock symbol?

How do I buy shares of Vyant Bio?

What is Vyant Bio's stock price today?

How much money does Vyant Bio make?

How can I contact Vyant Bio?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™